- Patients’ characteristics.
| Variables | n (%) |
|---|---|
| Female | 128 (62.7) |
| Mean age | 49.9 (19.2) |
| Mean weight | 61.7 (10.2) |
| Mean body mass index | 24 (4.2) |
| SSTI | |
| Exit site infection | 84 (41.2) |
| Wound infection | 72 (35.3) |
| Cellulitis | 44 (21.5) |
| Abscess | 4 (2.0) |
| Presence of fever | 163 (80.0) |
| Previous invasive procedures | 159 (77.9) |
| Recent chemotherapy | 155 (76) |
| Diabetes | 54 (26.5) |
| Recent radiotherapy | 21 (10.3) |
| Previous transfusion | 20 (9.8) |
| Appropriate antibiotics prescribed | 150 (73.5) |
| Antibiotics for culture negative infections (n=72) | |
| Piperacillin/tazobactam | 52 (72.2) |
| Ceftriaxone | 6 (8.3) |
| Vancomycin | 5 (6.9) |
| Cefuroxime | 5 (6.9) |
| Diabetes after chemotherapy | |
| No | 133 (65%) |
| Yes | 71 (35%) |
| Activity of chemotherapy | |
| Antimicotubules | 45 (32.4) |
| Alkylating agents/antimicotubules | 18 (12.9) |
| Antimetabolites | 14 (10.1) |
| Antimetabolites/alkylating/antimicotubules | 13 (9.4) |
| Antimicotubules/H2R | 12 (8.6) |
| Others* | 37 (26.6) |
| Types of chemotherapy | |
| Paclitaxel | 27 (18.9) |
| Docetaxel | 21 (14.7) |
| CHOP | 15 (10.5) |
| FOLFOX | 13 (9.1) |
| Paclitaxel/carboplatin | 10 (7.0) |
| Others† | 57 (39.9) |
| Frequency of chemotherapy | |
| Weekly | 51 (37.0) |
| Every 2 weeks | 46 (33.3) |
| Every 3 weeks | 40 (29.0) |
| Monthly | 1 (0.7) |
| Duration of chemotherapy | |
| 8 cycles | 22 (15.8) |
| 6 cycles | 15 (10.8) |
| 18 cycles | 12 (8.6) |
| 16 cycles | 11 (7.9) |
| 4 cycles | 9 (6.5) |
| 10 cycles | 9 (6.5) |
| 20 cycles | 8 (5.8) |
| Other cycles§ | 53 (38.1) |
↵* n=9 (Antimicotubules/Alkylating agents, Antimetabolites/Alkylating); n=6 (alkylating agents); n=2 (Topoisomerase II inhibitor/Alkylating agents, Topoisomerase I inhibitor, Antimetabolites/Topoisomerase I Inhibitor, Antimetabolites/Alkylating/Topoisomerase I inhibitor); n=1 (Antimetabolites/Alkylating agents, Antimetabolites/Alkylating/antibiotics/antimicotubules, antibiotics agents, antimetabolites/Alkylating/antibiotics, Antimetabolites/antibiotics),
↵† Capecitapine/oxaliplatin, paclitaxel/Trastusumab, IM methotrexate, cisplatin/paclitaxel, gemcitabine, oxaliplatin, FOLFIRI, irinotecan, docetaxel/trastuzumab, paclitaxel/FAC, paclitaxel/FEC, vinorelibine, PEB, methotrexate/doxorubicin, liposomal doxorubicin, paclitaxel/cisplatin, FOLFORINEX, FLOT, carboplatin, temozolomide, etoposide/carboplatin, FOLRINIX, FAC,
↵§ n=6 (12 cycles, 5 cycles); n=5 (7 cycles, 9 cycles, 13 cycles); n=4 (14 cycles, 21 cycles); n=5 (11 cycles, 22 cycles, 24 cycles); n=2 (3 cycles, 23 cycles); n=1 (4 cycles, 15 cycles, 17 cycles, 25 cycles, 28 cycles), CHOP: cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone, FOLFOX: folinic acid, fluorouracil, oxaliplatin